MassMutual Private Wealth & Trust FSB Buys 9,929 Shares of Integra LifeSciences Holdings Corporation $IART

MassMutual Private Wealth & Trust FSB increased its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 6,017.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,094 shares of the life sciences company’s stock after buying an additional 9,929 shares during the quarter. MassMutual Private Wealth & Trust FSB’s holdings in Integra LifeSciences were worth $124,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. CWM LLC raised its position in Integra LifeSciences by 413.8% in the 1st quarter. CWM LLC now owns 6,664 shares of the life sciences company’s stock valued at $147,000 after purchasing an additional 5,367 shares during the last quarter. Teacher Retirement System of Texas bought a new position in Integra LifeSciences in the 1st quarter valued at $223,000. Wealth Enhancement Advisory Services LLC bought a new position in Integra LifeSciences in the 1st quarter valued at $251,000. Dynamic Technology Lab Private Ltd acquired a new stake in shares of Integra LifeSciences in the 1st quarter valued at $277,000. Finally, Natixis Advisors LLC acquired a new stake in shares of Integra LifeSciences in the 1st quarter valued at $297,000. Institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Stock Down 8.1%

NASDAQ IART opened at $14.13 on Friday. The stock has a fifty day moving average of $13.81 and a 200-day moving average of $15.26. The stock has a market capitalization of $1.10 billion, a P/E ratio of -2.16 and a beta of 1.20. Integra LifeSciences Holdings Corporation has a 52 week low of $11.06 and a 52 week high of $27.13. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 EPS for the quarter, topping analysts’ consensus estimates of $0.43 by $0.02. Integra LifeSciences had a positive return on equity of 12.15% and a negative net margin of 30.87%.The business had revenue of $415.61 million during the quarter, compared to analysts’ expectations of $395.06 million. During the same period in the previous year, the firm earned $0.63 earnings per share. The firm’s quarterly revenue was down .6% compared to the same quarter last year. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, equities research analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.